Tin tức & Cập nhật
Xem bài viết Khớp
Xem

Dual-target oral drug outperforms tofacitinib in RA treatment
The novel, highly selective dual JAK1/TYK2 inhibitor TLL-018 appears to have better efficacy than the currently approved JAK inhibitor tofacitinib in the treatment of patients with rheumatoid arthritis (RA), according to the results of a head-to-head trial presented at EULAR 2023.

Pain mechanisms tied to disease activity in DMARD-treated RA
A recent study has shown the importance of identifying and treating aberrant peripheral and central pain regulation in patients with rheumatoid arthritis (RA) who are either initiating or switching to disease-modifying antirheumatic drug (DMARD) treatment.

Depression, anxiety symptoms saddle adolescents with JIA
Adolescents with juvenile idiopathic arthritis (JIA) remain vulnerable to symptoms of depression and anxiety, particularly panic, according to a study, noting the ongoing need for mental health screening protocols and services in this population.

Brepocitinib doses hold promise in treatment of psoriatic arthritis
Treatment with brepocitinib at 30 and 60 mg daily outperforms placebo at relieving signs and symptoms of psoriatic arthritis (PsA), with a safety profile consistent with that seen in other brepocitinib trials, according to data from a phase IIb study.




